Thomas Yau
About
Thomas Yau is a scholar working on Oncology, Hepatology and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, Thomas Yau has authored 210 papers receiving a total of 9.2k indexed citations (citations by other indexed papers that have themselves been cited), including 131 papers in Oncology, 108 papers in Hepatology and 52 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Thomas Yau's work include Hepatocellular Carcinoma Treatment and Prognosis (102 papers), Cancer Immunotherapy and Biomarkers (57 papers) and Colorectal Cancer Treatments and Studies (35 papers). Thomas Yau is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (102 papers), Cancer Immunotherapy and Biomarkers (57 papers) and Colorectal Cancer Treatments and Studies (35 papers). Thomas Yau collaborates with scholars based in Hong Kong, China and United States. Thomas Yau's co-authors include Ann‐Lii Cheng, Richard S. Finn, Ronnie T. P. Poon, Masatoshi Kudo, Pierre Chan, Philippe Merle, Tzy‐Jyun Yao, Andrew X. Zhu, Vikki Tang and Julien Edeline and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Medicine and Journal of Clinical Oncology.
In The Last Decade
Thomas Yau
199 papers receiving 9.1k citations
Hit Papers
Author Peers
Peers are selected by citation overlap in the author's most active subfields. citations · hero ref
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| Thomas Yau | 4.6k | 4.5k | 1.9k | 1.7k | 1.7k | 210 | 9.2k | |
| Lorenza Rimassa | 3.3k 0.7× | 2.7k 0.6× | 1.6k 0.9× | 1.3k 0.7× | 1.2k 0.7× | 269 | 6.6k | |
| Julien Caldéraro | 3.3k 0.7× | 3.4k 0.8× | 1.6k 0.9× | 3.2k 1.9× | 2.1k 1.2× | 164 | 10.2k | |
| Anthony B. El-Khoueiry | 3.6k 0.8× | 2.1k 0.5× | 1.6k 0.9× | 1.7k 1.0× | 795 0.5× | 308 | 6.5k | |
| Ronnie T. P. Poon | 3.5k 0.8× | 4.5k 1.0× | 1.7k 0.9× | 3.0k 1.7× | 2.3k 1.4× | 137 | 10.2k | |
| Ari David Baron | 7.6k 1.7× | 3.4k 0.7× | 3.4k 1.8× | 3.5k 2.0× | 852 0.5× | 71 | 12.9k | |
| Ronnie Tung‐Ping Poon | 2.3k 0.5× | 7.4k 1.6× | 1.7k 0.9× | 2.1k 1.2× | 3.7k 2.2× | 78 | 11.0k | |
| Sanjay Kakar | 3.0k 0.6× | 1.5k 0.3× | 1.3k 0.7× | 1.5k 0.9× | 1.7k 1.0× | 165 | 6.9k | |
| Tomoo Kosuge | 7.6k 1.7× | 3.7k 0.8× | 4.0k 2.1× | 2.0k 1.1× | 2.8k 1.7× | 218 | 13.7k | |
| Gamze Karaca | 4.6k 1.0× | 1.1k 0.3× | 1.2k 0.6× | 3.4k 2.0× | 1.5k 0.9× | 40 | 9.6k | |
| Jean‐Luc Van Laethem | 7.9k 1.7× | 1.1k 0.3× | 3.2k 1.7× | 1.4k 0.8× | 1.6k 1.0× | 275 | 10.4k |
Countries citing papers authored by Thomas Yau
Since
Specialization
Citations
This map shows the geographic impact of Thomas Yau's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Yau with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Yau more than expected).
Fields of papers citing papers by Thomas Yau
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Thomas Yau. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Yau. The network helps show where Thomas Yau may publish in the future.
Co-authorship network of co-authors of Thomas Yau
This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Yau. A scholar is included among the top collaborators of Thomas Yau based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Yau. Thomas Yau is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Lam, Ka-On, et al.. (2025). Trifluridine/Tipiracil (FTD/TPI) in Metastatic Colorectal Cancer in Hong Kong: A Territory-Wide Cohort Study. Advances in Therapy. 42(2). 1222–1236.
2.
Galle, Peter R., Thomas Decaens, Masatoshi Kudo, et al.. (2024). Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW.. Journal of Clinical Oncology. 42(17_suppl). LBA4008–LBA4008.
3.
Sangro, Bruno, Thomas Yau, Masatoshi Kudo, et al.. (2023). Exposure‐response analysis for nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma (CheckMate 040). Clinical and Translational Science. 16(8). 1445–1457.
4.
Segelov, Eva, Wei Wang, Gwo Fuang Ho, et al.. (2023). LBA29 Aspirin after standard adjuvant therapy for colorectal cancers (ASCOLT): An international, phase III, randomised, placebo-controlled trial. Annals of Oncology. 34. S1269–S1269.
5.
Vogel, Arndt, Robin Kate Kelley, Philip J. Johnson, et al.. (2023). Predictive and Prognostic Potential of Liver Function Assessment in Patients with Advanced Hepatocellular Carcinoma: A Systematic Literature Review. Liver Cancer. 12(4). 372–391.
6.
Cheung, Tan To, Daniel Wai‐Hung Ho, Qingyang Zhang, et al.. (2023). Multimodal Integrative Genomics and Pathology Analyses in Neoadjuvant Nivolumab Treatment for Intermediate and Locally Advanced Hepatocellular Carcinoma. Liver Cancer. 13(1). 70–88.
7.
Bauer, Todd M., Armando Santoro, Chia‐Chi Lin, et al.. (2023). Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors. Journal for ImmunoTherapy of Cancer. 11(11). e007353–e007353.
8.
Leung, Roland, Thomas Yau, Dennis A. Wong, John M. Luk, & Paul L. de Souza. (2023). Phase 1A, first-in-human study of ARB202, bispecific antibody to CDH17 and CD3, in advanced gastrointestinal malignancies expressing CDH17.. JCO Global Oncology. 9(Supplement_1). 25–25.
9.
Tan, Darren Jun Hao, Ansel Shao Pin Tang, Wen Hui Lim, et al.. (2023). Survival Trends in Sorafenib for Advanced Hepatocellular Carcinoma: A Reconstructed Individual Patient Data Meta-Analysis of Randomized Trials. Liver Cancer. 12(5). 445–456.
10.
Chan, Cerise Yuen‐Ki, David Kung‐Chun Chiu, Vincent Wai‐Hin Yuen, et al.. (2022). CFI-402257, a TTK inhibitor, effectively suppresses hepatocellular carcinoma. Proceedings of the National Academy of Sciences. 119(32). e2119514119–e2119514119.
11.
Li, Bryan, Thomas Yau, Roland Leung, et al.. (2021). Neoadjuvant Therapy with Concurrent Docetaxel, Epirubicin, and Cyclophosphamide (TEC) in High-Risk HER2-Negative Breast Cancers. Advances in Therapy. 38(12). 5752–5762.
12.
Kelley, Robin Kate, Tim Meyer, Lorenza Rimassa, et al.. (2020). Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma. Clinical Cancer Research. 26(18). 4795–4804.
13.
Kelley, Robin Kate, Jennifer Oliver, Saswati Hazra, et al.. (2020). Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design. Future Oncology. 16(21). 1525–1536.
14.
Finn, Richard S., Baek‐Yeol Ryoo, Philippe Merle, et al.. (2019). Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. Journal of Clinical Oncology. 38(3). 193–202.
15.
Chiu, Joanne, Roland Leung, Vikki Tang, et al.. (2019). Changing pattern of recurrences in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy in the era of dual anti-HER2 therapy. Postgraduate Medical Journal. 95(1121). 155–161.
16.
Yau, Thomas, Riccardo Lencioni, Wattana Sukeepaisarnjaroen, et al.. (2016). A Phase I/II Multicenter Study of Single-Agent Foretinib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma. Clinical Cancer Research. 23(10). 2405–2413.
17.
Chow, Ariel Ka-Man, Thomas Yau, Lui Ng, et al.. (2015). A preclinical study on the combination therapy of everolimus and transarterial chemoembolization in hepatocellular carcinoma.. PubMed Central. 5(8). 2376–86.
18.
Chiu, Joanne Wing Yan, Tzy‐Jyun Yao, Hilda Wong, et al.. (2012). The use of single‐agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child‐Pugh B liver cirrhosis. Cancer. 118(21). 5293–5301.
19.
Yau, Thomas, et al.. (2012). Management of gastric cancer: The Chinese perspective. The HKU Scholars Hub (University of Hong Kong). 1(2). 181–185.
20.
Hwang, Yu‐Yan, et al.. (2008). Massive rectal bleeding in a patient with a history of hepatocellular carcinoma: Figure 1. Gut. 57(10). 1412–1412.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Lorenza Rimassa Breakdown of academic impact, for papers by Julien Caldéraro Breakdown of academic impact, for papers by Anthony B. El-Khoueiry Breakdown of academic impact, for papers by Ronnie T. P. Poon Breakdown of academic impact, for papers by Ari David Baron Breakdown of academic impact, for papers by Ronnie Tung‐Ping Poon Breakdown of academic impact, for papers by Sanjay Kakar Breakdown of academic impact, for papers by Tomoo Kosuge Breakdown of academic impact, for papers by Gamze Karaca Breakdown of academic impact, for papers by Jean‐Luc Van Laethem